These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 6974214)

  • 21. Modification of the antitumor action of Corynebacterium parvum by stress.
    Turney TH; Harmsen AG; Jarpe MA
    Physiol Behav; 1986; 37(4):555-8. PubMed ID: 3092254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Failure of Corynebacterium parvum presensitization to modify the antitumor effects of systemic and local therapeutic injections of C. parvum in mice.
    Scott MT
    J Natl Cancer Inst; 1976 Mar; 56(3):675-7. PubMed ID: 815560
    [TBL] [Abstract][Full Text] [Related]  

  • 23. C. parvum immuntherapy of transplanted rat tumours.
    Pimm MV; Baldwin RW
    Int J Cancer; 1977 Dec; 20(6):923-32. PubMed ID: 591131
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Studies with a spontaneous mouse tumor. I. Growth in normal mice and response to Corynebacterium parvum.
    Woodruff MF; Whitehead VL; Speedy G
    Br J Cancer; 1978 Mar; 37(3):345-55. PubMed ID: 638014
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of local injection of Corynebacterium parvum on the growth of a murine fibrosarcoma.
    Woodruff MF; Dunbar N
    Br J Cancer; 1975 Jul; 32(1):34-41. PubMed ID: 1080671
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Corynebacterium parvum as an immunotherapeutic anticancer agent.
    Scott MT
    Semin Oncol; 1974 Dec; 1(4):367-78. PubMed ID: 4620441
    [No Abstract]   [Full Text] [Related]  

  • 27. Conditions favouring the selection of either specific or non specific C. parvum-mediated, systemic antitumour immunity in mice.
    Scott MT
    Dev Biol Stand; 1977 Apr 13-15; 38():273-6. PubMed ID: 415921
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of Corynebacterium parvum on tumour metastases in mice.
    Castro JE
    Br J Surg; 1977 Oct; 64(10):721-4. PubMed ID: 922293
    [No Abstract]   [Full Text] [Related]  

  • 29. Effects of Corynebacterium parvum alone and in combination with adriamycin in experimental tumor systems.
    Houchens DP; Johnson RK; Ovejera A; Gaston MR; Goldin A
    Cancer Treat Rep; 1976 Jul; 60(7):823-8. PubMed ID: 1009517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cell mediated immunity to Corynebacterium parvum and its role in tumor control.
    Tuttle RL
    Dev Biol Stand; 1977 Apr 13-15; 38():189-93. PubMed ID: 608505
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antitumor activity of purified cell walls from Corynebacterium parvum.
    Riveros-Moreno V; Bomford R; Scott MT
    J Natl Cancer Inst; 1978 Mar; 60(3):653-8. PubMed ID: 625069
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lymphocytes generated by in vivo priming and in vitro sensitization demonstrate therapeutic efficacy against a murine tumor that lacks apparent immunogenicity.
    Shu SY; Chou T; Sakai K
    J Immunol; 1989 Jul; 143(2):740-8. PubMed ID: 2738408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of Corynebacterium parvum.
    Milas L; Scott MT
    Adv Cancer Res; 1978; 26():257-306. PubMed ID: 343523
    [No Abstract]   [Full Text] [Related]  

  • 34. Positive correlation between the levels of natural killer cells and the in vivo resistance to syngeneic tumor transplants as influenced by various routes of administration of Corynebacterium parvum bacteria.
    Ojo E
    Cell Immunol; 1979 Jun; 45(1):182-7. PubMed ID: 455483
    [No Abstract]   [Full Text] [Related]  

  • 35. Macrophage mediated tumor cell cytotoxicity.
    Kaplan AM; Morahan PS
    Ann N Y Acad Sci; 1976; 276():134-45. PubMed ID: 1071961
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunomodulation in an apparently non-immunogenic murine tumor.
    Bursuker I; Petty BA; Neddermann KM; Keller LS
    Int J Cancer; 1991 Sep; 49(3):414-20. PubMed ID: 1833344
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of adriamycin and Corynebacterium parvum in tumor-bearing mice: modulation of response to sheep red blood cells.
    Dimitrov NV; Denny TN; Weisman MF; Cameron DG
    J Natl Cancer Inst; 1979 Aug; 63(2):423-6. PubMed ID: 379400
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Specific and nonspecific antitumor immunity. III. Specific T lymphocyte-mediated cytolysis of P815 mastocytoma and SL2 lymphoma by draining lymph node cells from syngeneic tumor-bearing DBA/2J mice.
    Germain RN; Williams RM; Benacerraf B
    Am J Pathol; 1976 Dec; 85(3):661-74. PubMed ID: 826167
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Histopathological aspects and macrophage reactivity in rats with Guerin's T8 viral tumor after treatment with Corynebacterium parvum].
    Caruso R; Bonina L; Chimicata S; Iannello D; Inferrera C; Mastroeni P
    Arch De Vecchi Anat Patol; 1979 Mar; 63(3):491-9. PubMed ID: 262125
    [No Abstract]   [Full Text] [Related]  

  • 40. Corynebacterium parvum and cyclophosphamide as combination treatment for a murine mammary adenocarcinoma.
    Purnell DM; Bartlett GL; Kreider JW; Biro TG
    Cancer Res; 1977 Apr; 37(4):1137-40. PubMed ID: 844041
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.